Circulating microRNA expression proﬁle in B-cell acute lymphoblastic leukemia by Luna Aguirre, Claudia Maribel et al.
Cancer Biomarkers 15 (2015) 299–310 299
DOI 10.3233/CBM-150465
IOS Press
Circulating microRNA expression profile in
B-cell acute lymphoblastic leukemia
Claudia Maribel Luna-Aguirrea, Margarita de la Luz Martinez-Fierrob, Fermín Mar-Aguilarc,
Idalia Garza-Velozb, Víctor Treviño-Alvaradod, Augusto Rojas-Martineza,e, Jose Carlos Jaime-Perezf ,
Guadalupe Ismael Malagon-Santiagoc, Cesar Homero Gutierrez-Aguirref , Oscar Gonzalez-Llanof,
Rosario Salazar-Riojasf , Alfredo Hidalgo-Mirandag, Herminia Guadalupe Martinez-Rodrigueza,
David Gomez-Almaguerf and Rocio Ortiz-Lopeza,e,∗
aDepartamento de Bioquímica y Medicina Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo
León, Monterrey NL, México
bLaboratorio de Medicina Molecular, Unidad Académica de Medicina Humana y Ciencias de la Salud,
Universidad Autónoma de Zacatecas, Zacatecas, México
cDepartamento de Biología Celular y Genética, Facultad de Ciencias Biológicas, Monterrey NL, México
dDepartamento de Ciencias Computacionales, ITESM, Campus Monterrey, Monterrey NL, México
eCentro de Investigación y Desarrollo en Ciencias de la Salud, Universidad Autónoma de Nuevo León, Monterrey,
México
fServicio de Hematología. Hospital Universitario Universidad Autónoma de Nuevo León, Monterrey NL, México
gInstituto Nacional de Medicina Genómica, México D.F. Periférico Sur, México
Abstract.
BACKGROUND: Acute lymphoblastic leukemia (ALL) is a highly diverse disease characterized by cytogenetic and molecular
abnormalities, including altered microRNA (miRNA) expression signatures.
AIM:We perform and validate a plasma miRNA expression profiling to identify potential miRNA involved in leukemogenesis
METHODS:MiRNA expression profiling assay was realized in 39 B-ALL and 7 normal control plasma samples using TaqMan
Low Density Array (TLDA) plates on Applied Biosystems 7900 HT Fast Real-Time PCR System. MiRNA validation was done
for six miRNA differentially expressed by quantitative real-time PCR.
RESULTS: Seventy-seven circulating miRNA differentially expressed: hsa-miR-511, -222, and -34a were overexpressed,
whereas hsa-miR-199a-3p, -223, -221, and -26a were underexpressed (p values < 0.005 for both sets). According to operating
characteristic curve analysis, hsa-miR-511 was the most valuable biomarker for distinguishing B-ALL from normal controls,
with an area under curve value of 1 and 100% for sensitivity, and specificity respectively.
CONCLUSIONS: Measuring circulating levels of specific miRNA implicated in regulation of cell differentiation and/or cell
proliferation such as hsa-miRNA-511, offers high sensitivity and specificity in B-ALL detection and may be potentially useful
for detection of disease progression, as indicator of therapeutic response, and in the assessment of biological and/or therapeutic
targets for patients with B-ALL.
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1. Introduction
Acute lymphoblastic leukemia (ALL) is a malignant
disorder of lymphoid progenitor cells characterized by
chromosomal abnormalities [1]. Treatment strategies
using risk-adapted chemotherapy cure more than 80%
of children with ALL; however, the disease relapses in
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20–30% of patients, who require intensive treatment
that associated with serious adverse events, including
death [2,3]. Besides, the survival rate for adults with
ALL remains below 40%. Although ALL can origi-
nate from either B or T lymphocyte progenitors, the
B-lineage is present in 85% and 75% of children and
adult cases of ALL, respectively [2,4].
MicroRNAs (miRNA) are non-coding, single-
stranded RNAs of 20–23 nucleotides in length that
constitute a class of gene regulators. They bind their
mRNA target counterparts to induce translational re-
pression, or to decrease their stability. MiRNA have
shown to control several biological processes [5], and
some of them possess oncogenic or tumor-suppressor
activity [6]. MiRNA genome-wide expression studies
have been conducted to study deregulated miRNA in
ALL. These studies have shown that malignant cells
of ALL patients have different miRNA expression pat-
terns from those in normal hematopoietic cells [7–10].
High expression of miR-33, miR-215, miR-369-5p,
miR-496, miR-518d, and miR-599 has been associated
with an unfavorable prognosis whereas high expres-
sion of a different set of miR-genes: miR-10a, miR-
134, miR-214, miR-484, miR-572, miR-580, miR-624
and miR-627 is associated with favorable prognosis
in pediatric ALL. The combined profile of these 14
miR-genes may predict the long-term clinical outcome
in children with ALL [11]. Some reports suggest that
these miRNA signatures combined with the analyses
of recurrent cytogenetic/molecular abnormalities are
helpful to classify subgroups and to define clinical out-
comes for this disease [12]. Despite the great contribu-
tions and advances in the ALL miRNA research, most
of the studies have been conducted in bone marrow
samples and peripheral blood mononuclear cells, while
the role of the circulating miRNA remains unclear. The
aim of this study was to evaluate the presence of a gen-
eral circulating miRNA expression profile in plasma
samples fromMexican B-ALL patients and controls to
define differentially expressed miRNA with potential
diagnostic use, and to define their ability to predict po-
tential biological targets.
2. Materials and methods
2.1. Samples collection
The study was approved by the Ethics Committee
of the Hospital Universitario, Universidad Autónoma
de Nuevo León, and written informed consent was ob-
tained from patients and subjects (Protocol ID BI08-
009). Peripheral blood samples were collected in tubes
with EDTA from 7 healthy donors (controls) and 39
patients with recently diagnosed and untreated ALL-
B at Servicio de Hematología, of Hospital Universi-
tario, Universidad Autónoma de Nuevo León (Mon-
terrey, Mexico). Plasma was separated from cellular
fractions and collected after centrifugation at 2,500
rpm for 5 minutes. An additional centrifugation round
at 14,000 rpm for 10 min at room temperature to
eliminate cellular debris was also performed. Obtained
plasma samples were used to prepare aliquots of 250 μl
and stored at −80◦C until further processing.
2.2. RNA isolation from human plasma samples
Total RNA for the miRNA profile was isolated as
follows: plasma samples were thawed on ice and to-
tal RNA (including miRNA) was isolated from 200 μl
of plasma using 700 μl of QIAzol Lysis Reagent and
RNeasy Mini spin columns of a commercially avail-
able Qiagen miRNeasy Mini Kit (Qiagen, UK), ac-
cording to manufacturer’s instructions, and eluted with
30 μl of elution buffer. Total RNA used in the valida-
tion stage was extracted from 200 μl of plasma with
600 μl of Trizol LS Reagent (Invitrogen, Carlsbad,
CA) coupled to precipitation with ethanol, according
to the manufacturer’s protocol and was resuspended in
20 μl of nuclease-freewater. Quality and RNA concen-
tration were determined by measuring the absorbance
at 260 nm and 260/280 ratio, respectively, using a Nan-
oDrop 1000 spectrophotometer (NanoDrop Technolo-
gies Inc., USA).
2.3. miRNA profiling using TaqMan low density array
(TLDA) plates
The expression analysis of the miRNA was per-
formed in three steps: reverse transcription, pre-
amplification step and real-time PCR, using Megaplex
Pools that consist of primers pools and microfluidic
plates of TaqMan Human MicroRNA Array set (v2.0)
to analyze 667 highly characterized human miRNA
(Applied Biosystems, Foster City, CA, USA) accord-
ing to manufacturer’s instructions. In brief, synthesis
of cDNA for mature miRNA was performed on 30–
1000 ng of total RNA from 2 controls, 1 pool of 3 con-
trols (with the same quantity of RNA), and 13 ALL-B
samples using the TaqMan miRNA reverse transcrip-
tion kit and Megaplex-RT Primers Human Pool A and
B (10X), which are pre-defined pools of 381 and 294
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RT primers respectively. The 7.5 μl RT reactions were
incubated at 16◦C for 2 min, 42◦C for 1 min, 50◦C for
1 sec, 40 cycles; 85◦C for 5 min and then held at 4◦C.
Subsequently, in order to enhance the ability to detect
low expressed miRNA, we pre-amplified the RT prod-
uct using 12.5 μl TaqMan preAmp Master Mix (2X),
2.5 μl Megaplex preAmp Primers Human Pool A and
B (10X), respectively, 7.5 μl nuclease-free water and
2.5 μl cDNA. The 25 μl reactions were incubated at
95◦C for 10 min, 55◦C for 2 min and 72◦C for 2 min,
followed by 12 cycles at 95◦C for 15 sec and 60◦C for
4 min. The thermal cycler used for synthesis of cDNA
and pre-amplification step was GeneAmp PCR Sys-
tem 9700 (Applied Biosystem). Finally, for the real-
time PCR, the 25 μl pre-amplified product was diluted
with 25 μl 0.1X Tris-EDTA buffer, take 9 μl of this di-
lution and mixture with 450 μl of TaqMan Universal
PCR Master Mix No AmpErase UNG (2X) and 441 μl
of nuclease-free water. Next, 100 μl of reaction mix-
ture was dispensed into each port of the TLDA, and the
cards were centrifuged and sealed. Quantitative real-
time PCR was run on Applied Biosystems 7900 HT
Fast Real-Time PCR System using default cycling con-
ditions. One sample and one control were run in du-
plicate. Quantification cycle (Cq) values were calcu-
lated using the SDS Relative Quantification software
v2.3 and RQ manager 1.2 (Applied Biosystems) using
automatic baseline settings and assigned threshold of
0.2.
2.4. Validation stage by qRT-PCR
RT was performed using the TaqMan miRNA RT-kit
and miRNA-specific primers (Applied Biosystems).
The 7.5 μl reaction mixture consisted of 0.75 μl of
Reverse-transcription buffer (10X), 0.095 μl of RNase
inhibitor (20 units/μl), 0.075 μl of dNTPs (100 mM)
with dTTP, 0.5 μl of Multi-Scribe reverse-transcriptase
(50 units/μl), 1.5 μl of primer, 100 ng of RNA, and
nuclease-free water. RT was performed in a PTC-100
Peltier Thermal Cycler (MJ Research) at 16◦C for
30 min, 42◦C for 30 min, and 85◦C for 5 min.
Quantitative real-time PCR was performed in tripli-
cate and included non-template negative controls. For
the 10 μl reactions, we combined 3.5 μl of nuclease-
free water, 5 μl of TaqMan Universal PCR Master Mix
Gene Expression (2X), 0.5 μl of the TaqMan miRNA
assay mix and 1 μl of cDNA. Amplification was per-
formed on a 7500 Fast Real-Time Systems (Applied
Biosystems) at 50◦C for 2 min and 95◦C for 10 min,
followed by 40 cycles at 95◦C for 15 s and 60◦C for
1 min.
2.5. Data analysis
High throughput data generated from TLDA plates
were analyzed using DataAssist v2.0 software (Ap-
plied Biosystems). To select the candidate reference
genes in the array plates, we performed quantile nor-
malization with SAM software to identify the miRNA
with lowest standard deviation between all samples,
including controls, and their stability was determined
by DataAssist v2.0 software (Applied Biosystems).
The miRNA with the lowest standard deviation and
better stability were selected for use in the poste-
rior validation experiments, focusing on a selection of
deregulated miRNA. Relative expression of miRNA
was determined employing multiple reference gene
normalization. Coefficient of variation, Spearman’s
correlation coefficient, similitude index and stability
(M) were determined for the generated data. In the
validation stage, relative gene expression of miRNA
was determined from RT-qPCR data by the 2−ΔΔCt
method, using the selected reference gene normaliz-
ers, and the results obtained from samples and con-
trols. U of Mann-Whitney or Student’s t test were
used to compare the patients with ALL and healthy
controls. The diagnostic properties of miRNA dereg-
ulated were evaluated using Receiver Operating Char-
acteristic curve (ROC) analysis. In all the compar-
isons the distribution of continuous data was deter-
mined using the D’Agostino-Pearson K2 test and the
significance level (α) of 0.05 was considered. Statis-
tical analyses were performed using SPSS 15.0 for
Windows (SPSS Software, USA) and Sigma plot soft-
ware v12. In the prediction of signaling pathways B-
ALL involved, according to the miRNA expression
profile identified, 19 miRNA that showed more differ-
ences in their expression levels between study groups
and the most significant p values for these differ-
ences were considered. Pathways analysis was real-
ized online using multiple miRNA analysis on DI-
ANA miRPath v2.0 software and KEGG PATHWAY
Database (http://www.genome.jp/kegg/pathway.html).
Additionally in gene target prediction for hsa-miR-
511 and hsa-miR-199a miRanda software was used
(http://www.microrna.org/microrna/getGeneForm.do).
3. Results
3.1. Patients
Demographic and clinical characteristics of patients
and controls are summarized in Table 1. Nineteen pa-
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Table 1
Clinical and biological characteristics of study population
Characteristic Cases group Controls
(n = 39) (n = 7)
Gender Male 21 (53.8 %) 2 (28.6%)
Female 18 (46.2 %) 5 (71.4%)
Age (years) Pediatric 19 (mean age: 7) 0
(range: 1–17)
Adult* 17 (median age: 36) 7 (median age: 26)
(range: 18–66) (range: 25–31)
MIC Early precursor B 1 (2.56 %) –
classification Common ALL 13 (33.33 %) –
Pre-B ALL 11 (28.22 %) –
B-cell ALL 14 (35.89 %) –
∗Age data for three adult B-ALL patients were not available.
tients were pediatric and 17 were adult (child-adult
ratio, 1.1), 21 were male and 18 were female (male-
female ratio, 1.2). Median ages for pediatric and adults
were 7 and 36 years, respectively. According to the
morphologic, immunologic, and cytogenetic (MIC)
classification [13], 1 patient (2.56%) was classified as
early B-precursor ALL, 13 (33.33%) as common ALL,
11 (28.22%) as pre-B ALL, and 14 (35.89%) as B-cell
ALL.
3.2. Establishment of reference genes for plasma
samples
Expression of 667 miRNA was measured in the
plasma from 13 B-ALL cases representing different
stage of maturation of B-ALL and from 5 plasma con-
trol samples. Prior to analyzing the expression profile
of circulating miRNA, the identification of internal ref-
erence miRNA that remain stably expressed for ALL
in plasma was realized through quantile normalization.
MiRNA that amplified in all samples with a Cq value
 36 were included in the analysis. One hundred forty
eight miRNA with these characteristics were studied;
ten of them were selected and their M values were
determined. Four of these miRNA: hsa-miR-106a and
hsa-miR-26b for the plate A, and hsa-miR-30a and hsa-
miR-30d for the plate B, respectively, showed the low-
est standard deviation values, high expression stability
values (M values of 0.6603 and 0.8323 for the miRNA
of the plate A, and M values of 1.1528 and 1.1108
for the miRNA of the plate B, respectively), therefore,
they were selected and used as internal reference genes
throughout the study.
3.3. Circulating microRNAs differentially expressed
in B-ALL
CirculatingmiRNA differentially expressed between
B-ALL cases and controls, were determined by data as-
sist software using as reference endogenous hsa-miR-
106a and hsa-miR-26b (plate A) and hsa-miR-30a and
hsa-miR-30d (plate B). We identified 77 miRNA dif-
ferentially expressed (p values < 0.05) in cases, with
an expression level greater than two (cutoff of 2) com-
pared to the healthy controls. Forty miRNA were over-
expressed at a significant higher level and the remain-
ing thirty-seven were underexpressed (Table 2). From
these, 39 miRNA have been associated previously to
leukemia and 38 miRNA have remained unpublished
(Table 2). The highest mean of expression level for an
overexpressed miRNA corresponded to hsa-miR-511,
(159.5 fold change, p = 0.002) while the most under-
expressed was hsa-miR-199a-3p (−13.48 fold change,
p < 0.001).
3.4. Validation of abnormal miRNA expression
MiRNA-specific RT-qPCR was used to confirm the
expression level of the most deregulated miRNA: three
overexpressed (hsa-miR-511, hsa-miR-34a and hsa-
miR-222), and three underexpressed (hsa-miR-26a,
hsa-miR-221 and miR-223) were selected for the val-
idation in 39 B-ALL samples (32 B-ALL cases) and
7 controls. The hsa-miR-106a and hsa-miR-26b were
considered as reference endogenous genes. Figure 1
and Table S1, show concordance between the TLDA
results and the validation using qRT-PCR for the six
selected miRNA (p values< 0.001). Expression levels
of hsa-miR-511, hsa-miR-34a, hsa-miR-222, hsa-miR-
26a, hsa-miR-221 and hsa-miR-223 ranged from 3.32
to 12.98, 0.73 to 7.55,−1.50 to 3.12,−1.63 to −9.17,
1.1 to −8.21, and 0.31 to −8.52, respectively (Figs 1B
and 1C); being the miRNA expression patterns inde-
pendently confirmed in B-ALL cases and controls.
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Table 2
B-ALL differential miRNA profile. Total RNA from 13 B-ALL samples and 5 health donors were included in the obtaining of miRNA differ-
entially expressed by TLDA platform. Relative quantification (RQ) was obtained considering as reference endogenous hsa-miR-106a and hsa-
miR-26b (plate A) and hsa-miR-30a and hsa-miR-30d (plate B) respectively (see material and methods for additional details). Reference column
displays previous reports for the specific miRNA
miRNA RQ p-value Type of miRNA RQ p-value Type of
overexpressed leukemia/Reference underexpressed leukemia/Reference
hsa-miR-511 159.55 0.002 hsa-miR-199a-3p −13.48 < 0.001
hsa-miR-34a∗ 98.56 0.015 CLL [45] hsa-miR-340∗ −7.03 < 0.001
hsa-miR-565 92.04 0.004 hsa-miR-151-3p −5.74 0.002 CLL [46]
hsa-miR-34a 20.03 0.004 CLL [45] hsa-miR-335 −4.94 < 0.001 AML [47]
hsa-miR-10b∗ 19.37 0.039 AML [48] hsa-miR-99b −4.51 < 0.001
hsa-miR-630 15.11 0.029 hsa-miR-425∗ −3.96 0.017
hsa-miR-610 13.64 0.035 hsa-miR-224 −3.95 0.001 AML [9]
hsa-miR-181a 13.24 0.013 CML, CLL,
AML [45,49,50]
hsa-miR-221 −3.89 < 0.001 CML, ALL, AML,
CLL [37,51–53]
hsa-miR-181c 9.26 0.014 hsa-miR-744 −3.86 < 0.001
hsa-miR-222 8.74 0.004 CML, ALL, AML,
CLL [35,51,53,54]
hsa-miR-15b −3.71 0.008 AML, APL [55,56]
hsa-miR-138-1∗ 7.74 0.031 CML [57] hsa-miR-223 −3.67 < 0.001 CLL, CML, ALL,
AML,
APL [58–62]
hsa-miR-363 7.44 0.006 AML [63] hsa-miR-26a −3.67 < 0.001 AML, ALL [64,65]
hsa-miR-144∗ 7.01 0.034 CML [51] hsa-miR-454∗ −3.56 0.005
hsa-miR-451 5.94 0.008 CML, ALL [35,66] hsa-miR-452 −3.55 0.001
hsa-miR-99a 5.51 0.048 CLL, ALL [11,67] hsa-miR-491-5p −3.39 < 0.001
has-miR-155 5.14 0.026 CLL, CML, ALL,
AML [36,45,68,69]
hsa-miR-340 −3.39 0.001
hsa-miR-886-3p 5.02 0.031 hsa-miR-196b −3.28 0.001 ALL, AML [52,70]
hsa-miR-223∗ 4.95 0.044 CML, CLL, AML,
ALL [58,60,71,72]
hsa-miR-301a −3.23 0.005
hsa-miR-422a 4.91 0.007 hsa-miR-324-5p −3.21 0.047
hsa-miR-146a 4.90 0.018 ALL, AML,
APL, CML,
CLL [36,46,73,74]
hsa-miR-126∗ −3.17 0.002 CLL, AML,
ALL [9,45,75]
hsa-miR-192 4.78 0.005 hsa-miR-152 −3.00 0.005 ALL [76]
hsa-miR-190b 4.40 0.022 hsa-miR-330-3p −2.92 0.041
hsa-miR-95 3.94 0.019 hsa-miR-652 −2.77 < 0.001
hsa-miR-140-3p 3.82 0.013 hsa-miR-374b −2.71 < 0.001
hsa-miR-660 3.77 0.005 CLL [45] hsa-miR-148b −2.59 < 0.001
hsa-miR-886-5p 3.60 0.021 hsa-miR-671-3p −2.57 0.002
hsa-miR-25 3.41 0.019 AML [36] hsa-miR-18a −2.52 0.046 ALL [77]
hsa-miR-320 3.28 0.014 AML [78] hsa-let-7d −2.44 0.003 APL [56]
hsa-miR-30e 3.18 0.024 hsa-miR-339-3p −2.32 0.013
hsa-miR-16 2.84 0.015 CLL, ALL,
APL [62,79,80]
hsa-miR-126 −2.32 < 0.001 CLL, AML,
ALL [9,45,75]
hsa-miR-19b 2.66 0.002 ALL [65] hsa-miR-30b −2.30 < 0.001 CLL [45]
hsa-miR-500 2.58 0.046 hsa-miR-148b∗ −2.25 0.004
hsa-miR-29a 2.56 0.042 AML, CLL [81,82] hsa-miR-27a −2.22 0.006 ALL, AML [18,36]
hsa-miR-502-3p 2.48 0.039 hsa-miR-30c −2.12 < 0.001 AML [83]
hsa-miR-195 2.39 0.002 CLL, AML [82,84] hsa-miR-374a −2.10 < 0.001
hsa-miR-20b 2.20 0.009 ALL [85] hsa-miR-331-3p −2.06 0.001
hsa-miR-579 2.17 0.029 hsa-miR-28-5p −2.05 < 0.001
hsa-miR-7 2.08 0.024 ALL [77]
hsa-miR-19a 2.05 0.01 CLL, CML [51,86]
hsa-miR-768-3p 2.04 0.043
ALL: Acute lymphoblastic leukemia. CLL: Chronic lymphoblastic leukemia. AML: Acute Myeloid leukemia. APL: Acute promyelocytic
leukemia. CML: Chronic myelocytic leukemia.
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Table 3
Evaluation of potential capacity for ALL diagnosis of miRNA selected
Parameter miRNA Overexpressed miRNA Underexpressed
miR-511 miR-34a miR-222 miR-26a miR-221 miR-223
Area under the ROC curve 1 0.98 0.91 0.91 0.92 0.93
Sensitivity 1 0.92 0.79 0.79 0.83 0.89
Specificity 1 1 1 1 1 1
PPV 1 1 1 1 1 1
NPV 1 0.70 0.54 0.47 0.54 0.64
ROC: Receiver Operating Characteristic; PPV: positive predictive value; NPV: negative predictive value.
A CB
Fig. 1. miRNA validation. Expression levels of six miRNA were validated using 39 samples from ALL patients, and 7 controls by qRT-PCR.
Figure 2A showsΔCq values (y axis) obtained for 3 miRNA initially overexpressed (hsa-miR-511, hsa-miR-34a, and hsa-miR-222, respectively),
and 3 miRNA underexpressed (hsa-miR-26a, hsa-miR-221, and hsa-miR-223 respectively) in the ALL group compared with the controls (x
axis). B and C plots illustrate the Log 2 of the ex pression levels (y axis) of the six miRNA included in the validation stage.
3.5. Evaluation of B-ALL diagnosis capacity of the
six miRNA validated
To assess the B-ALL diagnosis capacity of the six
circulating miRNA validated, their specificity, sensi-
tivity, positive and negative predictive values, were an-
alyzed by ROC curves (Table 3) and the associated
area under the curve (AUC). From the miRNA over-
expressed, the ROC values (including AUC) obtained
for hsa-miR-511 and hsa-miR-34a were better than
hsa-miR-222 and/or the three underexpressed genes
included in the analyses (hsa-miR-26a, hsa-miR-221
and hsa-miR-223), demonstrating their best B-ALL di-
agnosis capacity (Table 3). According to ROC anal-
ysis (highest values obtained in sensitivity and speci-
ficity parameters), theΔCq cutoff values for hsa-miR-
511, hsa-miR-34a, hsa-miR-222, hsa-miR-26a, hsa-
miR-221, and hsa-miR-223 were fixed in 9.458, 7.179,
−0.1325, 2.073, −0.1861, and −4.309 respectively.
Figure 2 shows a comparison between ΔCq values
obtained for hsa-miR-511, hsa-miR-34a, hsa-miR-222
in the study groups, and their respective cutoff val-
ues. Most of ΔCq values from controls samples were
grouped under the cutoffs fixed for each miRNA, con-
firming the diagnostic power of hsa-miR-511 and hsa-
miR-34a for B-ALL.
3.6. Pathways analysis and biological targets
In our study, pathways analysis of 19 miRNA (hsa-
miR-511, -19b, -195, -565, -34a, -222, -363, -181a, -
181c, -199a-3p, -340, -335, -99b, -221, -744, -223, -
26a, -224, and -151-3p)with different over or under ex-
pression, showed that mainly Wnt, MAPK, TGF-beta,
p53, Jak-STAT, NOTCH, and B and T cell receptor sig-
naling pathways (among others), are actively regulated
by these miRNA (Table S2 and Fig. 3 respectively).
When grouped by disease, KEGG pathways regulated
by these 19 miRNA included CML, AML, and other
cancers (see Table S2). Considering hsa-miR-511 only
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Fig. 2. Evaluation of ALL diagnosis capacity of hsa-miR-511, hsa-miR-34a, and hsa-miR-222. ALL diagnosis capacity of the miRNA with high
values of area under the ROC curve is shown in this figure. ΔCq cutoff values for hsa-miR-511, hsa-miR-34a, and hsa-miR-222 were fixed at
9.458, 7.179, and −0.1325, respectively, according to their highest values obtained in the sensitivity and specificity parameters. The vertical
dotted line shows that the ΔCq values obtained from controls samples are grouped within the cutoffs fixed for each miRNA (horizontal lines).
Study subjects are represented in the x axis, while y axis displays the expression level of hsa-miR-222, and hsa-miR-511, and hsa-miR-34a,
respectively.
(most overexpressed) and hsa-miR-199a-3p (most un-
derexpressed), about one hundred biological targets
were identified (100 for hsa-miR-511 and 98 for hsa-
miR-199a-3p, respectively). Common targets identi-
fied by the two miRNA included PPP3CC, AKT2,
RUNX1, and other genes belonging to the pathways
of Wnt signaling, MAPK signaling, the hematopoietic
cell lineage, and the chronic/acute myeloid leukemia
pathways, among others (Fig. 3).
4. Discussion
Previous studies have suggested improvements in
detecting malignancies by using specific extracellu-
lar miRNA that perform better than other markers
for disease classification [14]. The presence of al-
tered miRNA profiles in plasma has been reported
for several types of tumors, including CLL [15,16].
Since plasma-derived biomarkers are more accessi-
ble, simple to analyze, and correlate to malignant pro-
cesses [17], we investigated the expression profile of
miRNA in plasma of B-ALL patients. Compared to
healthy controls, 77 miRNAwere B-ALL differentially
Fig. 3. hsa-miR-511 and hsa-miR-199a-3p pathways analysis.
expressed. Thirty-nine of them were previously asso-
ciated with leukemia and 38 corresponded to unpub-
lished miRNA markers. Among these novel biomark-
ers, over-expression of hsa-miR-511, hsa-miR-565,
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hsa-miR-34a/a*, and hsa-miR-222, was more strongly
associated with B-ALL. A remarkable finding of this
study was the under-expression of hsa-miR-199a-3p,
hsa-miR-340*, hsa-miR-26a, hsa-miR-223, and hsa-
miR-151-3p. There is a discrepancy regarding the ex-
pression of hsa-miR-708, a marker associated with re-
lapse and favorable response to glucocorticoid therapy.
This molecule is reported as overexpressed in bone-
marrow samples of pediatric-ALL [18], in our study
this miRNA was over-expressed 94.2 times respect to
controls; however the difference observed only showed
a statistical trend (p = 0.058); the reason for these dif-
ferences is unclear to us, but this may reflect differ-
ences in miRNA concentrations between the blood and
the bone marrow milieus due to in situ differences in
production, transportation, and stability, among other
factors. With the exception of hsa-miR-151-3p (no
current association with disease), deregulated miRNA
observed in our study, have been associated with
other pathologies different than B-ALL. For example,
hsa-miR-511 is differentially expressed between non-
alcoholic steatohepatitis (NASH) patients and non-
NASH subjects [19]; the over-expression of hsa-miR-
34a (a modulator of p53 negative regulator MDM4) is
associated with hypermethylation in non Hodkin Lym-
phoma, and is also up-regulated in the squamous cell
lung carcinoma tissues [20–23], and hsa-miR-708 has
been associated with bladder, prostate, and lung can-
cer [24–27]. Finally, breast lobular neoplasia progres-
sion is related to up-regulation of hsa-miR-565 [28]
and deregulation of hsa-miR-199a-3p has been associ-
ated with Epstein-Barr virus-infection in diffuse large
B-cell lymphoma [29,30].
Regarding the validation of results, the accuracy
of miRNA expression data analysis depends on the
proper normalization to reach correct conclusions [31,
32]. TLDA platform includes 3 small nucleolar RNAs
(snoRNA) stably expressed in several tissues that are
useful as reference genes during data analyses; how-
ever, the expression of these genes was not a con-
stant in our samples. Some explanation for this result
is that the expression of these genes was evaluated in
tissues samples, but not in plasma. miRNA expression
may differ among biological fluids. Accordingly, se-
lection of endogenous controls is crucial for these stud-
ies. In this sense, hsa-miR-106a, hsa-miR-26b (from
plate A), hsa-miR-30a and hsa-miR-30d (from plate B)
showed to be the most appropriate endogenous control
for miRNA plasma normalization in B-ALL patients,
due to their stability (smaller M value). Although the
expression stability of these miRNA has been individ-
ually reported in some human tissues, cell lines [31],
prostate and breast cancer models [33], human plasma
and serum samples [34], this is the first report that eval-
uates their utility in plasma of B-ALL patients and we
postulated them as reference miRNA for this disease.
The B-ALL aberrant expression patterns identified
by TLDA for six of the most deregulated miRNA were
successfully confirmed using RT-qPCR in a greater
sample number and their diagnostic properties were
also assessed by ROC analysis. With the exception of
hsa-miR-511 and hsa-miR-34a, the circulating miRNA
validated in this study, have been previously associ-
ated with ALL [35–38] and we provide an additional
support for their role in the pathogenesis of this dis-
ease. ROC analysis showed that in plasma at ΔCt
cutoff of 9.458, hsa-miR-511 was the most valuable
biomarker for distinguishing B-ALL from normal con-
trols, with an AUC value of 1, and 100% of sensi-
tivity and specificity respectively; these values indi-
cate the maximum performance that can be reached in
a marker for B-ALL diagnosis. Remarkably, B-ALL
cases were not stratified considering any other variable
(age, sex, translocations, etc.) thereforewe suggest that
the miRNA biomarkers reported in this study are valid
for all the subjects with a diagnosis of B-ALL.
Pathway classifications related to 19 miRNA differ-
entially expressed revealed that the most significant
biological targets were genes involved in cell adhe-
sion (pathway KEGG ID: hsa04514, and hsa04510),
cell proliferation, differentiation, apoptosis (WNT and
MAPK signaling: KEGG IDs hsa04310 and hsa04010,
respectively), hematopoietic cell lineage (hsa04640),
and regulation of transcription (hsa03022). Target pre-
diction of hsa-miRNA-511 and hsa-miR-199a-3p (the
most overexpressed and underexpressed, respectively)
revealed that they may be involved in the KEGG path-
ways of CML (hsa05220) and AML (hsa05221). No-
tably, we found that the AKT2 and RUNX1 genes are
the shared targets for the two miRNA in myeloid
leukemia. AKT2 is a putative oncogene that plays a key
in regulating cell survival, insulin signaling, angiogen-
esis and tumor formation [39]. It has been previously
reported overexpressed in ovarian, pancreatic, breast,
prostate, renal, colon, lung, and hepatocellular cancer,
as well as in myeloid leukemia [40–42]. RUNX1 is
thought to be involved in the development of normal
hematopoiesis. Chromosomal translocations involving
this gene are well-documented and have been asso-
ciated with several types of leukemia [43,44]. There-
fore, AKT2 and RUNX1 are activated in human can-
cers and consequently may be considered in the de-
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sign of molecular therapies. These results showed that
miRNA-511 and hsa-miR-199a-3pmight be associated
with the pathogenesis of B-ALL, and can be used as
circulating biomarkers in the detection of the disease,
and potentially as ALL development and progression
markers.
5. Conclusion
Measuring circulating levels of specific miRNA im-
plicated in cell differentiation and/or cell proliferation
such as hsa-miRNA-511, offers high sensitivity and
specificity in B-ALL detection and may be potentially
used for the identification of progression markers and
in the assessment of biological and/or therapeutic tar-
gets for patients with B-ALL.
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